[{"address1": "142 North Cedros Avenue", "address2": "Suite B", "city": "Solana Beach", "state": "CA", "zip": "92075", "country": "United States", "phone": "858 925 8215", "website": "https://effector.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.", "fullTimeEmployees": 14, "maxAge": 86400, "priceHint": 4, "previousClose": 1.17, "open": 0.292, "dayLow": 0.2725, "dayHigh": 0.35, "regularMarketPreviousClose": 1.17, "regularMarketOpen": 0.292, "regularMarketDayLow": 0.2725, "regularMarketDayHigh": 0.35, "beta": 0.825, "forwardPE": -0.14226668, "volume": 1743853, "regularMarketVolume": 1743853, "averageVolume": 356064, "averageVolume10days": 89100, "averageDailyVolume10Day": 89100, "bid": 0.2513, "ask": 0.3738, "bidSize": 200, "askSize": 200, "marketCap": 1505881, "fiftyTwoWeekLow": 0.2725, "fiftyTwoWeekHigh": 22.5, "fiftyDayAverage": 1.7657, "twoHundredDayAverage": 9.91525, "currency": "USD", "enterpriseValue": 369158, "floatShares": 4580542, "sharesOutstanding": 4704410, "sharesShort": 110662, "sharesShortPriorMonth": 244035, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0235, "heldPercentInsiders": 0.0291, "heldPercentInstitutions": 0.23708001, "shortRatio": 0.73, "shortPercentOfFloat": 0.023699999, "impliedSharesOutstanding": 4704410, "bookValue": 0.212, "priceToBook": 1.5099057, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -34631000, "trailingEps": -12.57, "forwardEps": -2.25, "lastSplitFactor": "1:25", "lastSplitDate": 1705017600, "enterpriseToEbitda": -0.011, "52WeekChange": -0.93314284, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "EFTR", "underlyingSymbol": "EFTR", "shortName": "eFFECTOR Therapeutics, Inc.", "longName": "eFFECTOR Therapeutics, Inc.", "firstTradeDateEpochUtc": 1614609000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2ce11303-d138-3e2f-abbd-b04b9d454ccb", "messageBoardId": "finmb_240590335", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.3201, "targetHighPrice": 12.0, "targetLowPrice": 10.0, "targetMeanPrice": 11.0, "targetMedianPrice": 11.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 25383000, "totalCashPerShare": 5.396, "ebitda": -32593000, "totalDebt": 20248000, "quickRatio": 0.993, "currentRatio": 1.027, "debtToEquity": 2448.368, "returnOnAssets": -0.83328, "freeCashflow": -17665876, "operatingCashflow": -29191000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]